Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819915 | 0.80 | RPS6KB1 (0.64) | RPS6KB1MAPK14RAF1 | |
| SCHEMBL13487574 | 0.79 | MAPK14 (0.56) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3543192 | 0.79 | MAPK14 (0.65) | RPS6KB1NPSR1KDM4ENPC1RAB9A | |
| SCHEMBL3216985 | 0.79 | RPS6KB1 (0.47) | RPS6KB1NPSR1KDM4ENPC1RAB9A | |
| SCHEMBL3545513 | 0.76 | RPS6KB1 (0.68) | RPS6KB1NPC1RAB9AMAPK14MAPK13 | |
| SCHEMBL3549445 | 0.76 | MAPK14 (0.71) | RPS6KB1KDM4ENPC1RAB9AMAPK14 | |
| SCHEMBL3541451 | 0.76 | MAPK14 (0.65) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13487545 | 0.75 | RAF1 (0.56) | NPSR1RXFP1MAPK14MAPK13MAPK12 | |
| SCHEMBL4366522 | 0.73 | RPS6KB1 (0.58) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13487556 | 0.73 | MAPK14 (0.38) | RPS6KB1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | RPS6KB1 355/4885NPSR1 4769/4885KDM4E 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.